Periprocedural myocardial infarction occurs in at least 10% of percutaneous coronary intervention procedures and impacts long-term prognosis, warranting routine biomarker measurement and preventive drugs.
How can periprocedural myocardial injury be prevented during elective percutaneous coronary intervention?
Highlights the importance of routine biomarker measurement and antiplatelet therapy to assess and prevent periprocedural myocardial injury during elective PCI.
Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.
Cuculi et al. (Sat,) conducted a review in Periprocedural myocardial injury during percutaneous coronary intervention. Oral and intravenous antiplatelet agents and other drugs was evaluated on Periprocedural infarction (myocardial infarction type 4a). Periprocedural myocardial infarction occurs in at least 10% of percutaneous coronary intervention procedures and impacts long-term prognosis, warranting routine biomarker measurement and preventive drugs.